Potential clinical nephrotoxicity biomarkers

• CHUNG Bu-Young

  Division of Toxicology, College of Pharmacy, Sungkyunkwan University, Korea

• KWON Mi Jung

  Division of Toxicology, College of Pharmacy, Sungkyunkwan University, Korea

• KIM Min Ji

  Division of Toxicology, College of Pharmacy, Sungkyunkwan University, Korea

• NAM Yoon A

  Division of Toxicology, College of Pharmacy, Sungkyunkwan University, Korea

• KYUNG Minji

  Division of Toxicology, College of Pharmacy, Sungkyunkwan University, Korea

• BANG Du Yeon

  Division of Toxicology, College of Pharmacy, Sungkyunkwan University, Korea

• LIM Seong Kwang

  Division of Toxicology, College of Pharmacy, Sungkyunkwan University, Korea

• CHO Myung Chan

  Division of Toxicology, College of Pharmacy, Sungkyunkwan University, Korea

• KIM Young Woo

  Division of Toxicology, College of Pharmacy, Sungkyunkwan University, Korea

• KWACK Seung Jun

  Department of Biochemistry and Health Science, College of Natural Sciences, Changwon National University, Korea

• KIM Hyung Sik

  Department of Biochemistry and Health Science, College of Natural Sciences, Changwon National University, Korea

• LEE Byung-Mu

  Division of Toxicology, College of Pharmacy, Sungkyunkwan University, Korea

抄録

Nephrotoxicity is one of critical toxicological manifestations in clinical and preclinical investigation. Conventionally, serum creatinine and blood nitrogen urea (BUN) have been used for screening nephrotoxicity status. Advanced research in nephrotoxicity biomarkers was able to demonstrate promising biological molecules produced in biological fluids and tissues for the prediction of nephropathy. Of numerous nephrotoxicity biomarkers, some of them are comparatively evaluated for their potential usefulness. The biomarkers proposed are as follows: kidney injury molecule-1 (KIM-1), cystatin C (Cys), neutrophil gelatinase associated lipocalin (NGAL), N-acetyl-β-Dglucosaminidase (NAG) interleukin-18 (IL-18), and liver-type fatty acid binding protein (L-FABP). NGAL has been shown to detect kidney injury earlier than changes in serum creatinine (Scr) in kidney patients. Scr value at the time of diagnosis of acute kidney injury (AKI) or other types of kidney disorders may not provide a reliable diagnostic information about prognosis of kidney injury because it could not reflect the severity or the stage specificity of nephropathy. NGAL levels in urine may be better to predict nephrotoxicity due to its high sensitivity and specificity. Other metabolomic biomarker of citrate was also proposed as a potential useful target metabolite for nephrotoxicity induced by xenobiotics.<br>(Acknowledgement: This research was support by a grant (10182KFDA992-1203) from Korea Food & Drug Administration in 2010)

収録刊行物

• 日本毒性学会学術年会

  日本毒性学会学術年会 39.2 (0), AP-230-, 2012

  日本毒性学会

詳細情報

• CRID: 1390001205546753920
• NII論文ID: 130005009176
• DOI: 10.14869/toxpt.39.2.0.ap-230.0
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可